<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168937">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897754</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000560986</org_study_id>
    <secondary_id>ECOG-E3200T2</secondary_id>
    <nct_id>NCT00897754</nct_id>
  </id_info>
  <brief_title>Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab</brief_title>
  <official_title>Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
      help doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer. It may also help doctors understand how patients respond to treatment.

      PURPOSE: This laboratory study is looking at gene expression in patients with advanced or
      metastatic colorectal cancer receiving bevacizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether the balance of splice form expression alters susceptibility of tumors
           in vivo to respond to anti-VEGF therapy.

      OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory
      endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Mean scores for VEGFb and pan-VEGF gene expression by IHC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression as measured by tissue microarrays</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Splice form expression as measured by reverse transcriptase-PCR</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF165b protein expression as measured by ELISA</measure>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Tumor tissue samples available from patients with advanced or metastatic
             adenocarcinoma of the colon or rectum

               -  Receiving bevacizumab on clinical trial E-3200

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bates, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Bristol Heart Institute at University of Bristol</affiliation>
  </overall_official>
  <verification_date>September 2007</verification_date>
  <lastchanged_date>May 16, 2009</lastchanged_date>
  <firstreceived_date>May 9, 2009</firstreceived_date>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
